142 related articles for article (PubMed ID: 33508619)
1. Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia.
Wu Z; Zhang H; Wu M; Peng G; He Y; Wan N; Zeng Y
Biomed Pharmacother; 2021 May; 137():111299. PubMed ID: 33508619
[TBL] [Abstract][Full Text] [Related]
2. T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.
Sun L; Jiang G; Ng YY; Xiao L; Du Z; Wang S; Zhu J
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10189-10201. PubMed ID: 37270461
[TBL] [Abstract][Full Text] [Related]
3. Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in
Anthofer M; Windisch M; Haller R; Ehmann S; Wrighton S; Miller M; Schernthanner L; Kufferath I; Schauer S; Jelušić B; Kienesberger S; Zechner EL; Posselt G; Vales-Gomez M; Reyburn HT; Gorkiewicz G
Front Immunol; 2024; 15():1282680. PubMed ID: 38318189
[TBL] [Abstract][Full Text] [Related]
4. Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E; McLeish E; Blancafort P; Coudert JD; Gaudieri S
Front Immunol; 2021; 12():712722. PubMed ID: 34456921
[TBL] [Abstract][Full Text] [Related]
5. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia
Ibáñez-Navarro M; Fernández A; Escudero A; Esteso G; Campos-Silva C; Navarro-Aguadero MÁ; Leivas A; Caracuel BR; Rodríguez-Antolín C; Ortiz A; Navarro-Zapata A; Mestre-Durán C; Izquierdo M; Balaguer-Pérez M; Ferreras C; Martínez-López J; Valés-Gómez M; Pérez-Martínez A; Fernández L
Front Immunol; 2023; 14():1187665. PubMed ID: 37928520
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET
Lunn-Halbert MC; Laszlo GS; Erraiss S; Orr MT; Jessup HK; Thomas HJ; Chan H; Jahromi MA; Lloyd J; Cheung AF; Chang GP; Dichwalkar T; Fallon D; Grinberg A; Rodríguez-Arbolí E; Lim SYT; Kehret AR; Huo J; Cole FM; Scharffenberger SC; Walter RB
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473239
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes.
Ferguson Bennit HR; Gonda A; Kabagwira J; Oppegard L; Chi D; Licero Campbell J; De Leon M; Wall NR
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513976
[TBL] [Abstract][Full Text] [Related]
8. Genetic engineering of T cells for immunotherapy.
Ellis GI; Sheppard NC; Riley JL
Nat Rev Genet; 2021 Jul; 22(7):427-447. PubMed ID: 33603158
[TBL] [Abstract][Full Text] [Related]
9. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
10. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport F; Neelamraju Y; Baslan T; Hassane D; Gruszczynska A; Robert de Massy M; Farnoud N; Haddox S; Lee T; Medina-Martinez J; Sheridan C; Thurmond A; Becker M; Bekiranov S; Carroll M; Moses Murdock H; Valk PJM; Bullinger L; D'Andrea R; Lowe SW; Neuberg D; Levine RL; Melnick A; Garrett-Bakelman FE
Leukemia; 2021 Sep; 35(9):2688-2692. PubMed ID: 33580203
[No Abstract] [Full Text] [Related]
11. Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy.
Molgora M; Cortez VS; Colonna M
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546248
[TBL] [Abstract][Full Text] [Related]
12. Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.
Kam AYF; Piryani SO; Lee CL; Rizzieri DA; Spector NL; Sarantopoulos S; Doan PL
Mol Cancer Res; 2021 May; 19(5):886-899. PubMed ID: 33514658
[TBL] [Abstract][Full Text] [Related]
13. A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML.
Heimbruch KE; Meyer AE; Agrawal P; Viny AD; Rao S
Neoplasia; 2021 Mar; 23(3):337-347. PubMed ID: 33621854
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM; Escudero A; Mestre C; Fuster Soler JL; Martínez AP; Vagace Valero JM; Vela M; Ruz B; Navarro A; Fernández L; Fernández A; Leivas A; Martínez-López J; Ferreras C; De Paz R; Blanquer M; Galán V; González B; Corral D; Sisinni L; Mirones I; Balas A; Vicario JL; Valle P; Borobia AM; Pérez-Martínez A
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):328-337.e1. PubMed ID: 33610500
[TBL] [Abstract][Full Text] [Related]
15. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
16. Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S; Labadie BW; Argulian A; Patnaik A
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33572196
[TBL] [Abstract][Full Text] [Related]
17. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.
Wang T; Pine AR; Kotini AG; Yuan H; Zamparo L; Starczynowski DT; Leslie C; Papapetrou EP
Cell Stem Cell; 2021 Jun; 28(6):1074-1089.e7. PubMed ID: 33571445
[TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
[TBL] [Abstract][Full Text] [Related]
19. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy.
Rabilloud T; Potier D; Pankaew S; Nozais M; Loosveld M; Payet-Bornet D
Nat Commun; 2021 Feb; 12(1):865. PubMed ID: 33558546
[TBL] [Abstract][Full Text] [Related]
20. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Samur MK; Fulciniti M; Aktas Samur A; Bazarbachi AH; Tai YT; Prabhala R; Alonso A; Sperling AS; Campbell T; Petrocca F; Hege K; Kaiser S; Loiseau HA; Anderson KC; Munshi NC
Nat Commun; 2021 Feb; 12(1):868. PubMed ID: 33558511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
